natgillin/translations-raw huggingface dataset:
The use of a solid form of the compound of formula I, its hydrates or solvates, its salts and hydrates or solvates of its salts according to any one of the claims 1 to 8 for the preparation of a medicament for the treatment of treatment of a proliferative disease selected from a benign or malignant tumor, carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma, glitoblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a turnor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, lymphomas, a mammary carcinoma or a leukemia. 
Farmaceutski sastav prema zahtjevu 3, naznačen time, da obuhvaća od1% do20% djelotvorne tvari ili djelotvornih tvari. Kristalni oblik prema zahtjevu 1 ili 2, naznačen time, da se upotrebljava za liječenje proliferativne bolesti odabrane između sljedećih: benigni ili maligni tumor, karcinom mozga, bubrega, jetre, nadbubrežne žlijezde, mjehura, dojke, želuca, gastrički tumori, karcinom jajnika, debelog crijeva, zadnjeg crijeva, prostate, gušterače, pluća, vagine ili tiroidne žlijezde, sarkom, glioblastomi, višestruki mijelom ili gastrointestinalni rak, posebno karcinom debelog crijeva ili kolorektalni adenom ili tumor vrata i glave, epidermalna hiperproliferacija, psorijaza, hiperplazija prostate, neoplazija, neoplazija epitelijalnih karakteristika, limfomi, karcinom maternice, leukemija, Cowdenov sindrom, Lhermitte-Dudos-bolest i sindrom Bannayan-Zonana.
ET-743 is currently formulated as a sterile lyophilized product containing 250 pg active substance per dosage unit, 250 mg mannitol as a bulking agent and 0.05 M phosphate buffer at pH 4 in order to solubilize ET-743. 
ET-743 je trenutno oblikovan kao sterilni liofilizirani proizvod koji sadrži 250 ug aktivne tvari po jedinici doze, 250 mg manitola kao punila i 0.05 Ivi fosfatnog pufera na pH 4 u cilju otapanja ET-743.
capturing the frame sizes in byte of every video frame n subsequent to an initial I-frame into a multiple of arrays, where each of these arrays is associated to a specific basic pattern of one of the considered GoP-structures and also has the length of said basic pattern, wherein step a) is performed by applying an algorithm depicted by the following symbolic code: so that for the specific array, representing the true GoP-structure to be detected, P-frames are always added up with P-frames and B-frames are always added up with B-frames;. 
digitaliziranja veličina kadrova u bajtu svakog video kadra n koji dolazi nakon početnog I-kadra u više matrice, iskorištavanja značajki transportnog sloja koji nosi video tok, gdje svaka matrica od tih više matrica ima različitu veličinu, ArraySize[BP], jednaku duljini osnovnog uzorka tipa kadrova, BP, za svaku razmatranu strukturu GoP-a, gdje se veličinu svakog kadra n pribraja u n % ArraySize[BP]-ti element svake matrice, Array[BP], te gdje se bilježi broj veličina kadrova pribrojanih u svaki element svake matrica, što opisuje sljedeći simbolički kod:
The extended release dosage form of any one of claims 1 to 12, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, 80 mg, 90 mg, 120 mg or 160 mg of oxycodone hydrochloride. 
Postupak prema zahtjevu 40, naznačen time da oblik davanja sadrži 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg ili 160 mg oksikodon hidroklorida.
The method according to claim 16, wherein the combining step (a) is selected from the group consisting of: 
Postupak proizvodnje papira ili ploče prema zahtjevu 14 ili 15, gdje se korak kombiniranja (a) izabire iz skupine koja se sastoji od:
The average degree of polymerisation (DP) of polydextrose is about 12. 
Srednji stupanj polimerizacije (degree of polymerisation, DC) polidekstroze je oko 12.
Inecalcitol for the use according to anyone of claims 1 to 3 which comprises the administration of said doses of inecalcitol, at a frequency chosen from every three days, every other day (qod), once-a-day (qd), twice-a-day (bid) and three times a day (tid). 
Inekalcitol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se navedena upotreba sastoji u primjeni navedenih doza inekalcitola, gdje se odabranu učestalost bira između svaka tri dana, svakog drugog dana (god), jednom dnevno (gd), dvaput dnevno (bid), te tri puta dnevno (tid).
The vector of claim 1, wherein the heterologous dsRNA is short hairpin RNA (shRNA). 
Vektor za primjenu prema zahtjevu 1, naznačen time, što je heterologna dsRNK kratka RNK u obliku ukosnice (ShRNA).
where Y represents a hydrogen atom or a hydroxyl group (provided that if Y is a hydrogen atom, the 1-position is of S-configuration), 
RE gdje Y predstavlja atom vodika ili hidroksil skupinu (uz uvjet da ako Y je atom vodika, 1-položaj je u S-konfiguraciji),
wherein R1, R2 and R3 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl provided, however, at least one of R1, R2 and R3 is other than hydrogen, the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of less than 2, and the crosslinked amine polymer has an equilibrium proton binding capacity and a chloride binding capacity of at least 5 mmol/g in Simulated Gastric Fluid (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH1.2 and 37° C. 
, R2 i R3 su neovisno vodik, hidrokarbil, supstituirani hidrokarbil, uz uvjet da je ipak najmanje jedan od R1, R2 i R3 različit od vodika, umreženi aminski polimer ima ravnotežni omjer bubrenja u deioniziranoj vodi od 5 ili niži; umreženi aminski polimer veže odgovarajući molarni odnos kloridnih iona prema ometajućim ionima od najmanje 0,35:1, u puferu s ometajućim ionima na 37°C pri čemu su ometajući ioni fosfatni ioni i ometajući ionski pufer je otopina na pH 5,5 36mM klorida i 20mM fosfata.
Differential Scanning Calorimetry (DSC) has been used for the determination of the melting point (onset temperature in °C) of asenapine maleate. 
Diferencijalna skening kalorimetrija (DSC) rabljena je za određivanje točke tališta (početna temperatura u *C) asenapin maleata.
The chimeric polypeptide of claim 1, wherein the CBD has at least 80%, preferably 90%, amino acid sequence identity with the polypeptide of SEQ ID NO: 4. 
Kimerni polipeptid u skladu s patentnim zahtjevom 1, naznačen time što je aminokiselinski slijed CBD najmanje 80%, po mogućnosti 90%, identičan s polipeptidom sa SEQ ID NO: 4.
Two especially preferred glass fibers are available from the Manning Paper Company of Troy, New York, under the designations, Manniglas 1000 and Manniglas 1200. 
Dva naročito poželjna staklena vlakna pristupačna su od Manning Paper Company of Troy, New York, pod oznakama Manniglass 1000 1 Manniglass 1200.
For purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. 
Za svrhe oralnog davanja, tablete koje sadrže razne sastojke kao što su natrij-citrat, kalcij-karbonat i kalcij-fosfat mogu se koristiti zajedno s raznim sredstvima za sitnjenje kao što su poželjno škrob iz krumpira i tapioke, alginska kiselina 1 izvjesni kompleksni silikati, zajedno sa sredstvima za vezanje kao što su polivinilpirolidon, saharoza, želatin i akacija.
The pharmaceutical product for use according to claim 7, wherein the amounts of Compound I, or a pharmaceutically-acceptable salt thereof, and hydroxypropyl methyl cellulose acetate succinate in said complex are in a ratio of from about 1:9 to about 5:5, respectively. 
Farmaceutski proizvod za uporabu prema patentnom zahtjevu 7, naznačen time, da su količine spoja I, ili njegove farmaceutski prihvatljive soli, i hidroksipropil metil-celuloznog acetat sukcinata u navedenom kompleksu u omjeru od oko 1:9 odnosno do oko 5:5.
Optional additional ingredients include antimicrobrials, plasticizers, and antifoaming agents. 
Izborni dodatni sastojci obuhvaćaju antimikrobna sredstva, plastifikatore i sredstva protiv stvaranja pjene.
A polypeptide comprising a N-terminal first fragment of toxin A and a C-terminal second fragment of toxin B, wherein 
drugi fragment je fragment ponavljajuće domene toksina B iz bakterije C. difficile;
iii) the glycan comprises a reactive aldehyde group; iv) the glycan comprises an oxidized saccharide residue comprising a reactive aldehyde group; or 
11) -glikan sadrži reaktivnu aldehidnu skupinu; iv) < glikan sadrži oksidirani saharidni ostatak koji sadrži reaktivnu aldehidnu skupinu; ili vV) - glikan je vezan na efektorski dio.
epimerizing Compound (C-1) or a pharmaceutically acceptable salt thereof to form Compound (C) or a pharmaceutically acceptable salt thereof. 
(i) -epimeriziranju Spoja (C-1), ili njegove farmaceutski prihvatljive soli, kako bi se dobilo Spoj (C)
is selected from H, C1-C3 alkyl and cyclohexyl, optionally substituted with at least one C1-C3 alkyl group; 
Rio je izabran od H, C;-Cs alkila 1 cikloheksila, izborno supstituiranog s najmanje jednom C,-C3 alkil grupom;
or a pharmaceutically acceptable salt thereof. The compound according to claim 7, which is: 3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-(4-fluoro-fenil)-5-trifluorometil-piridin-2-karboksilna kiselina-(3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
They did not appear sedated. 
Nisu postali sedirani.
Magnesium (0.35 g, 0.0145 mol) was reacted with absolute methanol (10 ml) (in the presence of one drop of CC14) to give a solution of Mg(OCH3)2 in methanol solution. 
Magnezij (0,35 g, 0,0145 mola) tretiran je s apsolutnim metanolom (10 ml) (u prisustvu jedne kapi CCL) da bi dao otopinu Me(OCH>;), u metanolnoj otopini.
The speed of the rotor was set at 450 rev/min in the first 15 minutes of the pelletization and later kept at 600 rev/min. 
Brzina rotora održavana je na 450 okr/min tijekom prvih 15 minuta granuliranja i nakon toga na 600 okr/min.
STEP C: heating the mixture of STEP B to a temperature in the range of from 60°C to 65°C; 
KORAK C: zagrijavanje smjese iz KORAKA B do temperature u rasponu od 60*C do 65"C,
breaking the adduct of the quinine and Compound (C-1) by treating the adduct with HCl to form Compound (C-1) or a pharmaceutically acceptable salt thereof; 
(h) rastavljanju adukta kinina sa Spojem (C-1) obradom adukta s HCI kako bi se dobilo Spoj (C-1), ili njegovu farmaceutski prihvatljivu sol;
Also, the coating inhibits fungal mold growth and with appropriate additives inhibits bacterial growth on the surface of the produce. 
Također, oblaganje inhibira rast gljivica i sa odgovarajućim aditivima inhibira rast bakterija na površini proizvoda.
a leader sequence, such as the human VK3LP peptide, is coupled to the N-terminus of the RNase or the N-terminus of the DNase. 
vodeća sekvenca, kao stoje ljudski VK3LP peptid, je vezana naN-terminalni kraj RNaze.
Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which is halogen, or 1-4C-alkyl, 
Harl je izborno supstituiran s R6111 i/ili R6112 i monociklički je ili kondenzirani biciklički 5- do 10-eročlani nezasićeni heteroaromatski prsten, koji sadrži jedan do tri heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik 1 sumpor, gdje R6111 je halogen ili 1-4C-alkal, R6112 je 1-4C-alkil,
The method of aspect 28, wherein the composition has a form selected from the group consisting of a capsule, tablet, and pill. The method of aspect 28, wherein the compound is selected from the group consisting of RD162′, RD162", RD 169, or RD170, or a pharmaceutically acceptable salt thereof. 
PATENTNI ZAHTJEVI Spoj koji ima formulu: FR GL Et (RDS: ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku liječenja hiper-proliferacijskog poremećaja, naznačen time, da je hiper-proliferativni poremećaj odabran iz skupine koja se sastoji od benigne hiperplazije prostate, karcinoma dojke, i karcinoma jajnika.
a heavy chain variable region CDR2 amino acid sequence selected from the group consisting of SEQ ID NOs: 9-14; and 
(b) varijabilno područje jakog lanca CDR2 aminokiselinske sekvence odabrane iz skupine koju čine od SEQ ID NO:9 do SEQ ID NO:14;1
A comprehensive description of prodrugs and prodrug derivatives are described in: 
Detaljan opis derivata prolijekova i prolijeka opisani su u:
The method of claim 1, wherein the cumulative total amount of glutamate per unit volume in said medium is less than approximately 1 mM. 
Postupak prema Zahtjevu 1, naznačen time, što je kumulativna ukupna količina glutamata po jedinici volumena u spomenutom mediju manja od približno 1 mM,
computing means and means for a real time communication (300), with an operative Headquarter, said means embedding a function of reporting, through access to a data base, the completed activities of intervention, with storage of the technical and photographic documents related to the accident. 
- > sredstvo za proračunavanje i sredstvo za komuniciranje (300) s operativnim stožerom u realnom vremenu, navedeno sredstvo preko pristupa bazi podataka uključuje funkciju izvještavanja o provedenim aktivnostima intervencije, s pohranom tehničkih i fotografskih dokumenata koji se odnose na nezgodu.
reacting a compound of Formula III with a compound having the Formula IV in the presence of an organo hypervalent iodine reagent; or 
reakciju spoja formule III [image] sa spojem Formule IV [image] u prisutnosti organo hipervalentnog reagensa joda; ili
The Reinforcement system (29) according to claim 8, wherein the reinforcement system has at least two reinforcement layers (16) with or without a space between them and the at least one spacer (1) is directly connected with the at least two reinforcement layers (16). 
HR P20180554 T1 naznačen time što ojačanje ima najmanje dva ojačavajuća sloja (16), složena uz ili bez međusobnog razmaka, gdje je najmanje jedna razmaknica (1) izravno povezana s najmanje dva ojačavajuća sloja (16).
A compound selected from the group consisting (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide; and pharmaceutically acceptable salts thereof for use in the treatment of mania. 
Spoj naznačen time da je odabran iz skupine koju čine (25)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2- ilmetil)-sulfamid i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja manije.
Once an individual becomes symptomatic for Huntington's disease the course of the disease can last anywhere from ten to thirty years. 
Jednom kada se kod osobe pojave simptomi Huntington-ove bolesti, tijek bolesti može trajati negdje od deset do trideset godina.
The antibody or antibody fragment according to at least one of the preceding claims, wherein the C1ORF32 ectodomain variant polypeptide possesses at least 90% sequence identity with the amino acid sequences in SEQ ID NO: 299, SEQ ID NO: 147 or SEQ ID NO: 148 
Fuzijski protein prema najmanje jednom od patentnih zahtjeva 11 do 14, naznačen time da ima sekvencu kao što je navedeno u SEQ ID NO: 105.
a securement structure in the cargo compartment of the vehicle that releasably secures the packaging rack in the cargo compartment. 
pričvrsnu konstrukciju u teretnom odjeljku vozila (240), koja odvojivo pričvršćuje rešetkasto postolje za pakiranje (243) u teretnom odjeljku (241).
and pharmaceutically acceptable salts thereof. In particular embodiments R is selected from the group consisting of n-propyl and ethyl. 
Spoj prema zahtjevu 1, naznačen time, što je R izabran iz grupe koja sadrži n-propil i etil.
In certain embodiments of formula I, R1 is a group of formula A3: wherein Ra, Rb and Rc are as defined herein. 
Spoj prema zahtjevu 1, naznačen time, da R' je skupina formule A1, formule A2 ili formule A3: Al;
The compound of claim 18, wherein the -(C1-C6) alkyl group is a tert -butyl group or an iso-propyl group. 
Spoj prema zahtjevu 18, naznačen time da -(C;-Cx) alkilna skupina je tert-butilna skupina ili iso-propilna skupina.
In a form suitable for oral administration as film-coated dosage forms for Intact swallowing or as dosage forms capable of disintegration in the oral cavity, wherein the amount of iron oxy-hydroxide per dosage form Is > 300 mg. 
Farmaceutski pripravak prema zahtjevima 1 ili 2, u obliku prikladnom za oralnu primjenu kao filmom obloženi dozirni oblik za cjelovito gutanje ili kao dozirni oblik sposoban za raspadanje u oralnoj šupljini.
The panel according to claim 6, wherein the two projecting parts are separated by two flanges, each of the two flanges having a length L 13 oriented in the plane P framing a central rib comprising a top center part having a height H 14 and two lateral wings extending from the top center part on either side and downward, forming an angle a with the plane P, the width L 13, the heights H 7, H 14 and the angles B and a meet the following relationship: 
Ploča prema zahtjevu 5, naznačena time što su dva izbočena dijela (6, 6") odvojeni s dva osnovna dijela (13, 13) duljine L13 koji su smješteni u ravnini P koja okružuje središnje rebro koje se sastoji od njegovog središnjeg dijela (14) visine H14 i dva bočna krila (15, 15") koja produžuju gornji središnji dio s njegove obje strane i prema dolje, tvoreći kut o s ravninom P, širine L13, visine H7, H14 i kutovi fi š su u skladu sa sljedećim odnosima:
Composition according to any one of the preceding claims, wherein the composition contains at least 0.1%, preferably at least 0.3%, of a fructosazine selected from the group consisting of 2,5-deoxyfructosazine, 2,6-deoxyfructosazine, 2,5-fructosazine, 2,6-fructosazine and combinations thereof, by weight of dry matter. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što pripravak sadržava najmanje 0,1%, poželjno najmanje 0,3%, fruktozazina odabranog iz skupine koju sačinjavaju 2,5-deoksifruktozazin, 2,6- deoksifruktozazin, 2,5-fruktozazin, 2,6-fruktozazin i njihove kombinacije, po masi suhe tvari.
A genetically modified mouse, wherein the genetic modification comprises a replacement of a genomic fragment of the endogenous mouse low affinity FcYR gene locus, wherein said genomic fragment comprises the mouse genes encoding FcYRIIB, FcYRIII, and FcYRIV a-subunits, with a human genomic fragment that encodes at least two low affinity human FcYR genes, wherein the at least two low affinity human FcYR genes comprise a gene encoding a human FcYRIIIA a-subunit, wherein the mouse expresses a human FcYRIIIA protein associated with an endogenous mouse FcR Y-subunit, wherein the human FcYRIIIA protein is expressed on the surface of a mouse NK cell. 
Genetski modificirani miš, naznačen time, što se genetska modifikacija sastoji od zamjene genomskog fragmenta endogenog mišjeg lokusa gena FcyR s niskim afinitetom, pri čemu se spomenuti genomski fragment sastoji od mišjih gena koji kodiraju FcyRIIB, FeyRIII 1 FeyRIV a-podjedinice, s humanim genomskim fragmentom koji kodira najmanje dva humana gena FcyR s niskim afinitetom, pri čemu najmanje dva humana gena FcyR s niskim afinitetom sadrže humanu FeyRIIA a-podjedinicu koja kodira gene, pri čemu miš izražava humani protein FeyRIIIA povezan s endogenom mišjom FcR y-podjedinicom, pri čemu se humani FcyRIIIA protein izražava na površini mišje NK stanice.
The doses of the compounds used did not modify the blood pressure nor the heart rate of the animals. 
Upotrijebljena doza spojeva nije promijenila krvni tlak, niti ritam srca životinja.
Lactose monohydrate, microcrystalline cellulose, the active ingredient, the hydroxypropyl methyl cellulose and a portion of the croscarmellose sodium (in accordance with the formula) were screened into a 10 Litre Fielder high-shear blender (any suitable high shear blender could be used) and blended for 5 minutes at 300 rpm with the chopper off. 
Laktoza monohidrat, mikrokristalna celuloza, aktivni sastojak, hidroksipropil metil celuloza i dio kroskarameloza natrija (u skladu s formulom) se prosije u 10-litrenu Fielder miješalicu s visokim smicanjem (može se upotrijebiti bilo koja miješalica s visokim smicanjem) i miješa 5 minuta pri 300 okr/min s isključenim vibratorom.
A speech decoding method of the present invention is a speech decoding method using a speech decoding device for decoding an encoded speech signal and including: a bit stream separating step in which the speech decoding device separates a bit stream received from outside the speech decoding device that includes the encoded speech signal into an encoded bit stream and linear prediction coefficients; a linear prediction coefficient interpolating/extrapolating step in which the speech decoding device interpolates or extrapolates the linear prediction coefficients in a temporal direction; and a temporal envelope shaping step in which the speech decoding device shapes a temporal envelope of a speech signal by performing linear prediction filtering in a frequency direction on a high frequency component represented in a frequency domain by using the linear prediction coefficients interpolated or extrapolated in the linear prediction coefficient interpolating/extrapolating step. 
Postupak dekodiranja govora u kojem se upotrebljava naprava za dekodiranje govora za dekodiranje kodiranog govornog signala, naznačen time što se postupak dekodiranja govora sastoji u: koraku osnovnog dekodiranja, u kojem naprava za dekodiranje govora dekodira struju bitova koja sadrži kodirani govorni signal kako bi se dobilo niskofrekventnu komponentu, gdje struja bitova dolazi izvan naprave za dekodiranje govora; koraku pretvorbe frekvencije, u kojem naprava za dekodiranje govora pretvara niskofrekventnu komponentu dobivenu u koraku osnovnog dekodiranja u frekventno područje;
A polynucleotide encoding the VL domain of SEQ. 
Polinukleotid koji kodira VL domenu sa SEQ.
The topical veterinary composition of paragraph 10, wherein the at least second active agent is an anthelmintic active agent selected from thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an aryloazol-2-yl cyanoethylamino active agent. 
Topikalni veterinarski pripravak prema zahtjevu 7, naznačen time, da najmanje druga djelatna tvar je antihelmintska djelatna tvar odabrana od tiabendazola, oksibendazola, mebendazola, fenbendazola, oksfendazola, albendazola, triklabendazola, febantela, levamisola, pirantela, morantela, prazikvantela, klozantela, klorsulona, djelatne tvari aminoacetonitrila, i djelatne tvari ariloazol-2-il-cijanoetilamina.
Method for treating water at low cost, and for using it in a downstream industrial process (2), that purifies the water and eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the method comprising: 
Postupak za obradu vode uz nizak trošak, pri čemu postupak pročišćava vodu i uklanja suspendirane krute tvari u vodi filtriranjem manjeg dijela od ukupnog volumena vode, naznačen time što postupak obuhvaća:
A container according to claim 11, wherein the adhesive label is permanently affixed to the inner package by a connection portion extending about substantially the entire periphery of the adhesive label, wherein said portion is connected to the adhesive label along an edge of the adhesive label adjacent an edge of the access portion. 
Spremnik (600) prema zahtjevu 5, naznačen time da je naljepnica (608) trajno pričvršćena na unutrašnje pakiranje (606) pomoću spojnog ruba naljepnice (608) susjednog rubu pristupnog dijela, te je spojni rub smješten prema stražnjem dijelu vrha unutrašnjeg pakiranja.